Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 83

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 83
---
, our pro forma as adjusted net tangible book value per share after giving effect to this offering would have been $9,102,762 or $0.11 per share of common stock. This represents an immediate increase in as adjusted net tangible book value of $1.01 per share to our existing stockholders, and an immediate dilution of $0.16 per share to new investors purchasing securities in this offering at the assumed public offering price. The final public offering price will be determined between us, Dawson James and investors in the offering and may be at a discount to the current market price. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final public offering price. The following table illustrates this dilution on a per share basis:

| Assumed public offering price per share and accompanying Series Warrants                                                                                   
 Historical net tangible book value per share as of September 30, 2024                                                                                      | ​ | ​ 
 ​ | (0.68) | ​ | ​ | 0.27 | ​ |
|:-----------------------------------------------------------------------------------------------------------------------------------------------------------|:--|:--|-------:|:--|:--|-----:|:--|
| Pro forma decrease in net tangible book value per share attributable to the Vivus Adjustments                                                              | ​ | $ |  -0.22 | ​ | ​ |    ​ | ​ |
| Pro forma net tangible book value per share as of September 30, 2024, after giving effect to Vivus Adjustments                                             | ​ | $ |  -0.90 | ​ | ​ |    ​ | ​ |
| Pro forma as adjusted increase (or decrease) in net tangible book value per share attributable to investors in this offering and the Pro Forma Adjustments | ​ | $ |   1.01 | ​ | ​ |      | ​ |
| Pro Forma as adjusted net tangible book value per share after giving effect to this offering                                                               | ​ | ​ |        | ​ | $ | 0.11 | ​ |
| Dilution per share to investors participating in this offering                                                                                             | ​ | ​ |        | ​ | $ | 0.16 | ​ |

A $0.10 increase in the assumed public offering price of $0.269 per share, which is the last reported sale price of our common stock on The Nasdaq Capital Market on February 6, 2025, would result in an increase in our as adjusted net tangible book value per share after this offering by approximately $0